| 1. |
- Archer, Trevor, 1949, et al.
(författare)
-
Pharmacogenomics and Personalized Medicine in Mood Disorders
- 2013
-
Ingår i: Omics for Personalized Medicine. - New Delhi : Springer. - 9788132211839 ; :309, s. 309-334
-
Bokkapitel (refereegranskat)abstract
- Pharmacogenomics and the search for personalized medicine focus on the attainment of individualized pharmacotherapies that cover genetic variation and target groups of patients that present neurodevelopmental aspects of symptom profiles and biomarkers underlying the pathophysiology of mood disorders. The identification of genetic biomarkers facilitates choice of treatment, prediction of response, and prognosis of outcome over a wide spectrum of symptoms associated with affective states thereby optimizing clinical practice procedures. Several strategies, under development and refinement, show the propensity for derivation of essential elements in the etiopathogenesis of disorder affecting drug efficacy, drug metabolism, and drug adverse effects, e.g., with regard to SSRIs; these include the following: transporter gene expression and genes encoding receptor systems, hypothalamic-pituitary-adrenal axis factors, neurotrophic factors, and inflammatory factors affecting neuroimmune function. Nevertheless, procedural considerations of pharmacogenetics presume the parallel investment of policies and regulations to withstand eventual attempts at misuse thereby ensuring patient integrity
|
|
| 2. |
- Archer, Trevor, 1949, et al.
(författare)
-
Pharmacogenomics and Personalized Medicine in Parkinsonism
- 2013
-
Ingår i: Omics for Personalized Medicine. Barh D., Dhawan D., Ganguly N. (eds). - New Delhi : Springer. - 9788132211839 ; , s. 265-287
-
Bokkapitel (refereegranskat)abstract
- Pharmacogenetic-pharmacogenomic development from a single gene approach to incorporate pathway-based and genome-wide approaches has been benefi tted from the emergence of several parallel technologies, such as genomics, transcriptomics, metabolomics, and proteomics which have contributed to and enhanced significantly propensities for generation and testing of pharmacogenomic hypotheses both paralleled and followed by associated developments in the clinical practice for treating Parkinson’s disease (PD). The notion of “personalized medicine,” incorporating the customization of healthcare, with decisions and practices that suited to each individual patient through application of genetic, biomarker, gene- environment interactive, or other information, involves principles through which drugs, drug combinations, and drug administration properties are optimized for each individual’s unique genetic makeup. The personalized medication of antiparkinsonian drug therapy; the symptomatic and regional disruptions; genetic, epigenetic, and biomarkers of the disorder; and the pharmacogenomics of neuroleptic drug-induced parkinsonism provide outlets for eventual understanding and management. As a case study in personalized medicine in the laboratory, physical exercise combined with the electromagnetic wavelength treated Saccharomyces cerevisiae yeast, Milmed, was demonstrated to abolish the marked hypokinesia induced by the dopamine (DA) neurotoxin, MPTP, as well as the severe loss of DA in the striatal region of the C57/BL6 mice studied. The Exercise-Milmed coadministration induced also a profound increase in brain-derived neurotrophin levels (BDNF) in the mouse parietal cortex region that included the motor cortex
|
|
